Miguel Navarro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8282868/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	A pol I transcriptional body associated with VSG mono-allelic expression in Trypanosoma brucei. Nature, 2001, 414, 759-763.	27.8	304
3	New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource. Scientific Reports, 2015, 5, 8771.	3.3	204
4	Autophagy in protists. Autophagy, 2011, 7, 127-158.	9.1	148
5	Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proceedings of the United States of America, 2008, 105, 14579-14584.	7.1	121
6	NUP-1 Is a Large Coiled-Coil Nucleoskeletal Protein in Trypanosomes with Lamin-Like Functions. PLoS Biology, 2012, 10, e1001287.	5.6	105
7	Regulation of vsg expression site transcription and switching in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1998, 91, 77-91.	1.1	97
8	Trypanosoma brucei variant surface glycoprotein regulation involves coupled activation/inactivation and chromatin remodeling of expression sites. EMBO Journal, 1999, 18, 2265-2272.	7.8	76
9	The molecular karyotype of the megabase chromosomes of Trypanosoma brucei stock 427. Molecular and Biochemical Parasitology, 2000, 111, 261-273.	1.1	73
10	Cohesin regulates <i>VSG</i> monoallelic expression in trypanosomes. Journal of Cell Biology, 2009, 186, 243-254.	5.2	73
11	Nuclear repositioning of the VSG promoter during developmental silencing in Trypanosoma brucei. Journal of Cell Biology, 2007, 176, 133-139.	5.2	71
12	Third target of rapamycin complex negatively regulates development of quiescence in <i>Trypanosoma brucei</i> . Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14399-14404.	7.1	70
13	High-Throughput Screening Platform for Natural Product–Based Drug Discovery Against 3 Neglected Tropical Diseases: Human African Trypanosomiasis, Leishmaniasis, and Chagas Disease. Journal of Biomolecular Screening, 2015, 20, 82-91.	2.6	70
14	The Susceptibility of Trypanosomatid Pathogens to PI3/mTOR Kinase Inhibitors Affords a New Opportunity for Drug Repurposing. PLoS Neglected Tropical Diseases, 2011, 5, e1297.	3.0	70
15	SUMOylation by the E3 Ligase TbSIZ1/PIAS1 Positively Regulates VSG Expression in Trypanosoma brucei. PLoS Pathogens, 2014, 10, e1004545.	4.7	48
16	New tubulins in protozoal parasites. Current Biology, 2000, 10, R258-R259.	3.9	47
17	Identification and Characterization of Hundreds of Potent and Selective Inhibitors of Trypanosoma brucei Growth from a Kinase-Targeted Library Screening Campaign. PLoS Neglected Tropical Diseases, 2014, 8, e3253.	3.0	47
18	Nuclear architecture underlying gene expression in Trypanosoma brucei. Trends in Microbiology, 2007, 15, 263-270.	7.7	45

MIGUEL NAVARRO

#	Article	IF	CITATIONS
19	The AMPKα1 Pathway Positively Regulates the Developmental Transition from Proliferation to Quiescence in Trypanosoma brucei. Cell Reports, 2016, 17, 660-670.	6.4	44
20	Target of Rapamycin (TOR)-like 1 Kinase Is Involved in the Control of Polyphosphate Levels and Acidocalcisome Maintenance in Trypanosoma brucei. Journal of Biological Chemistry, 2010, 285, 24131-24140.	3.4	43
21	In situ analysis of a variant surface glycoprotein expression-site promoter region in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1998, 94, 53-66.	1.1	40
22	Establishment of a Structure–Activity Relationship of 1 <i>H</i> -Imidazo[4,5- <i>c</i>]quinoline-Based Kinase Inhibitor NVP-BEZ235 as a Lead for African Sleeping Sickness. Journal of Medicinal Chemistry, 2014, 57, 4834-4848.	6.4	35
23	Trypanosome TOR as a major regulator of cell growth and autophagy. Autophagy, 2009, 5, 256-258.	9.1	30
24	Identification of "Preferred―Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing?. ACS Infectious Diseases, 2016, 2, 180-186.	3.8	28
25	Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 203-212.	3.4	27
26	Target of rapamycin (TOR) kinase in <i>Trypanosoma brucei</i> : an extended family. Biochemical Society Transactions, 2013, 41, 934-938.	3.4	26
27	Targeted disruption of expression site-associated gene-1 in bloodstream-form Trypanosoma brucei. Molecular and Biochemical Parasitology, 1996, 81, 65-79.	1.1	24
28	Defeating Leishmania resistance to Miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: A proof of mechanism for trypanosomatid chemotherapy. Journal of Controlled Release, 2012, 161, 835-842.	9.9	24
29	Co-dependence between trypanosome nuclear lamina components in nuclear stability and control of gene expression. Nucleic Acids Research, 2016, 44, 10554-10570.	14.5	23
30	Increased uracil insertion in DNA is cytotoxic and increases the frequency of mutation, double strand break formation and VSG switching in Trypanosoma brucei. DNA Repair, 2012, 11, 986-995.	2.8	21
31	Molecular evidence of a Trypanosoma brucei gambiense sylvatic cycle in the human african trypanosomiasis foci of Equatorial Guinea. Frontiers in Microbiology, 2015, 6, 765.	3.5	20
32	Conditional expression of glycosylphosphatidylinositol phospholipase C in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1999, 103, 35-48.	1.1	19
33	Trypanosome TOR complex 2 functions in cytokinesis. Cell Cycle, 2009, 8, 697-699.	2.6	19
34	From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. ACS Infectious Diseases, 2017, 3, 225-236.	3.8	19
35	Inverted repeat structure and homologous sequences in the LD1 amplicons of Leishmania spp Molecular and Biochemical Parasitology, 1994, 68, 69-80.	1.1	18
36	The identification of circular extrachromosomal DNA in the nuclear genome of Trypanosoma brucei. Molecular Microbiology, 2003, 47, 277-289.	2.5	18

MIGUEL NAVARRO

#	Article	IF	CITATIONS
37	Trypanosomes lacking uracil-DNA glycosylase are hypersensitive to antifolates and present a mutator phenotype. International Journal of Biochemistry and Cell Biology, 2012, 44, 1555-1568.	2.8	18
38	Dynamics and size polymorphisms of minichromosomes in Leishmania major LV-561 cloned lines. Molecular and Biochemical Parasitology, 1992, 55, 65-74.	1.1	16
39	RNA pol II subunit RPB7 is required for RNA pol lâ€mediated transcription in <i>Trypanosoma brucei</i> . EMBO Reports, 2009, 10, 252-257.	4.5	16
40	Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models. PLoS Pathogens, 2016, 12, e1005851.	4.7	16
41	SUMOylated SNF2PH promotes variant surface glycoprotein expression in bloodstream trypanosomes. EMBO Reports, 2019, 20, e48029.	4.5	15
42	Localization of serum resistance-associated protein in <i>Trypanosoma brucei rhodesiense</i> and transgenic <i>Trypanosoma brucei brucei</i> . Cellular Microbiology, 2015, 17, 1523-1535.	2.1	13
43	Identification of sequence-specific promoters driving polycistronic transcription initiation by RNA polymerase II in trypanosomes. Cell Reports, 2022, 38, 110221.	6.4	13
44	Location in the source chromosome of the 180-kb minichromosome of Leishmania major and characterization of the novel junction. Molecular and Biochemical Parasitology, 1995, 71, 153-161.	1.1	11
45	Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics. Journal of Medicinal Chemistry, 2020, 63, 2527-2546.	6.4	11
46	Glossina palpalis palpalis populations from Equatorial Guinea belong to distinct allopatric clades. Parasites and Vectors, 2014, 7, 31.	2.5	10
47	Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5- <i>b</i>]pyridazines for the Treatment of Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2020, 63, 756-783.	6.4	10
48	Diamine and aminoalcohol derivatives active against Trypanosoma brucei. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 440-443.	2.2	8
49	Trypanosoma brucei gambiense Adaptation to Different Mammalian Sera Is Associated with VSG Expression Site Plasticity. PLoS ONE, 2013, 8, e85072.	2.5	8
50	Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2021, 64, 9404-9430.	6.4	6
51	The protozoan nucleus. Molecular and Biochemical Parasitology, 2016, 209, 76-87.	1.1	5
52	Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3629-3635.	2.2	5
53	Involvement in surface antigen expression by a moonlighting FG-repeat nucleoporin in trypanosomes. Molecular Biology of the Cell, 2018, 29, 1100-1110.	2.1	5
54	Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for <i>Trypanosoma brucei</i> Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 9912-9927.	6.4	5

MIGUEL NAVARRO

		15	<u> </u>
#	ARTICLE	IF	CITATIONS
55	Evaluation of a class of isatinoids identified from a high-throughput screen of human kinase inhibitors as anti-Sleeping Sickness agents. PLoS Neglected Tropical Diseases, 2019, 13, e0007129.	3.0	4
56	Structure–property studies of an imidazoquinoline chemotype with antitrypanosomal activity. RSC Medicinal Chemistry, 2020, 11, 950-959.	3.9	3
57	Role of RPB7 in RNA pol I transcription in Trypanosoma brucei. Molecular and Biochemical Parasitology, 2011, 180, 43-44.	1.1	2
58	Cohesin regulates <i>VSG</i> monoallelic expression in trypanosomes. Journal of Experimental Medicine, 2009, 206, i17-i17.	8.5	0